StreetAlpha
13F holdings · Q3 2026

Sphera Funds Management

Tel Aviv, L3 · files as Sphera Funds Management Ltd.
Know the moment Sphera Funds Management filesYou follow Sphera Funds Management An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1496201

Sphera Funds Management reported 100 stocks worth $660M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are MLYS (5.0%), TEVA (4.9%) and ALNY (4.5%). Compared with Q2 2026, the fund opened new positions in TEVA, SOXX and META, added to ALNY, CYTK and BBIO, trimmed MLYS, TSEM and SNDX and sold out of INSM, SEDG and XENE.

Latest filing: what Sphera Funds Management did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
22 new30 added34 trimmed19 sold outBought about $219M · sold about $199M
New 22
See all 22 →
Added 30
See all 30 →
Trimmed 34
  • Cybin Inc−$15.1M−76%
  • ORIC−$5.4M−54%
  • TSEM−$5.4M−22%
  • CLDX−$4.9M−62%
  • BIIB−$4.7M−22%
See all 34 →
Sold out 19
See all 19 →

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$660M−5.5% vs last quarter · $707M including options
Stocks held10022 new · 19 sold out
Top 5 weight21.3%spread out
Turnover63%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
MLYS
Mineralys Therapeutics Inc
$33.2M5.0%1.3M−148K (−10%)8 of 8
2
TEVA
Teva Pharmaceutical Industries Ltd
$32.5M4.9%821KNew position1 of 8
3
ALNY
Alnylam Pharmaceuticals Inc
$29.8M4.5%121K+110K (+1017%)2 of 8
4
CYTK
Cytokinetics Inc
$23.9M3.6%362K+142K (+65%)8 of 8
5
SOXX
Ishares Semiconductor
$21M3.2%37KNew position1 of 8
6
BBIO
Bridgebio Pharma Inc
$20.5M3.1%312K+66K (+27%)8 of 8
7
TSEM
Tower Semiconductor Ltd
$19.3M2.9%85K−24K (−22%)8 of 8
8
SNDX
Syndax Pharmaceuticals Inc
$18.9M2.9%1M−7,328 (−1%)8 of 8
9
BMRN
Biomarin Pharmaceutical Inc
$17.6M2.7%293K−35K (−11%)4 of 8
10
BIIB
Biogen Inc
$17.1M2.6%76K−21K (−22%)8 of 8
🔒 90 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
TEVA PHARMACEUTICAL INDS LTD
$50.8M1.5M
INSM
Insmed Inc
$12.7M119K
SEDG
Solaredge Technologies Inc
$7.7M4M
XENE
Xenon Pharmaceuticals Inc
$6.3M105K
ZBIO
Zenas Biopharma Inc
$5.9M231K

🔒 Free account: see all 19.

Options

valued at the underlying shares
StockTypeValueSharesChange
XBI
Spdr Series Trust
Put$11.8M75K−75,000
ARKG
ARK Genomic Revolution
Put$10.8M200K+200,000
CYBIN INC
Call$3.7M300K+300,000
PRAX
Praxis Precision Medicines I
Call$3.6M13K0
TRVI
Trevi Therapeutics Inc
Call$3.6M250K+250,000

🔒 Free account: see all 13.

Reported value

last 8 quarters
$541MQ4 '24
$405MQ1 '25
$382MQ2 '25
$422MQ3 '25
$479MQ4 '25
$581MQ1 '26
$699MQ2 '26
$660MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Sphera Funds Management 13F FAQ

What does Sphera Funds Management own?

Sphera Funds Management reported 100 stocks worth $660M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are MLYS (5.0%), TEVA (4.9%) and ALNY (4.5%). The table above lists every position in the filing (the top 10 without an account).

What did Sphera Funds Management buy and sell in Q3 2026?

Compared with Q2 2026: 22 new positions, 30 added to, 34 trimmed and 19 sold out. New positions include TEVA, SOXX and META. It sold all of INSM, SEDG and XENE.

When will Sphera Funds Management file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Sphera Funds Management's portfolio worth?

The Q3 2026 filing reports $660M in US stocks ($707M including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.